<div class="data-table" role="region" aria-labelledby="table-aod-fa" tabindex="0">
  <table class="table" itemscope itemtype="https://schema.org/Table">
  <caption id="table-aod-fa" itemprop="about"><span class="font-weight-bold">Tableau.</span> Anticoagulants oraux directs pour la prévention thromboembolique de la fibrillation atriale en 2022</caption>
  <thead>
    <tr>
      <th scope="col">Molécule</th>
      <th scope="col" class="text-right">Standard (mg)</th>
      <th scope="col" class="text-right">Allégée (mg)</th>
      <th scope="col" class="text-right">Réduite (mg)</th>
      <th scope="col">Quand réduire la dose</th>
    </tr>
  </thead>
  <tbody>
    <tr class="table-active">
      <th scope="row">Apixaban (x 2/j)</th>
      <td class="text-right">5</td>
      <td></td>
      <td class="text-right">2,5</td>
      <td>&ge; 2 parmi: âge &ge; 80, poids &le; 60 kg, créatininémie &ge; 133 µmol/L</td>
    </tr>
    <tr>
      <th scope="row">Dabigatran (x 2/j)</th>
      <td class="text-right">150</td>
      <td class="text-right">110</td>
      <td></td>
      <td>Âge &ge; 80, vérapamil ou risque hémorragique augmenté</td>
    </tr>
    <tr>
      <th scope="row">Rivaroxaban (1/j)</th>
      <td class="text-right">20</td>
      <td></td>
      <td class="text-right">15</td>
      <td>Clairance 15-49 mL/min</td>
    </tr>
  </tbody>
  </table>
</div>
<blockquote class="mt-2">
  <p lang="en">
    <a href="https://doi.org/10.1093/eurheartj/ehaa612" rel="external nofollow noopener"
      >Hindricks G. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Hear Jour. Vol 42. Issue 5. 1 Feb 2021. Pages 373–498.</a
    >
  </p>
</blockquote>
